Entera Bio (NASDAQ:ENTX) Shares Down 8.1% - What's Next?

Key Points

• Entera Bio shares fell 8.1% to about $3.19 in Wednesday trading, with volume substantially below the stock’s average daily volume.
• Analyst opinions remain mixed: HC Wainwright maintained a “buy” rating, while Weiss Ratings and Wall Street Zen rated the stock “sell.” The overall consensus is “Hold,” with an average price target of $9.00.
• Entera Bio reported a quarterly loss of $0.14 per share, missing the $0.08 consensus loss estimate. The clinical-stage biotech is developing oral peptide therapies, including its lead osteoporosis candidate, EB613.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) fell 8.1% during trading on Wednesday . The company traded as low as $3.23 and last traded at $3.1890. Approximately 119,456 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 1,112,857 shares. The stock had previously closed at $3.47.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ENTX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a research note on Friday, July 17th. Wall Street Zen raised shares of Entera Bio to a "sell" rating in a research note on Saturday, August 8th. Finally, HC Wainwright restated a "buy" rating on shares of Entera Bio in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Entera Bio has a consensus rating of "Hold" and an average price target of $9.00.

Entera Bio Price Performance

The company has a market capitalization of $556.08 million, a PE ratio of -9.11 and a beta of 1.38. The stock's 50 day simple moving average is $2.29 and its 200-day simple moving average is $1.62.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, equities analysts predict that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ENTX. Renaissance Technologies LLC boosted its stake in shares of Entera Bio by 338.4% in the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company's stock valued at $526,000 after buying an additional 365,441 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock worth $1,157,000 after acquiring an additional 29,629 shares during the last quarter. Jane Street Group LLC grew its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock worth $144,000 after acquiring an additional 43,536 shares in the last quarter. Superstring Capital Management LP purchased a new stake in shares of Entera Bio in the 4th quarter valued at approximately $33,000. Finally, HighTower Advisors LLC raised its holdings in shares of Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after purchasing an additional 25,000 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source